MARKET

ACHV

ACHV

Achieve
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.92
-0.36
-4.35%
After Hours: 7.92 0 0.00% 18:52 09/20 EDT
OPEN
8.23
PREV CLOSE
8.28
HIGH
8.25
LOW
7.88
VOLUME
162.57K
TURNOVER
--
52 WEEK HIGH
16.10
52 WEEK LOW
6.63
MARKET CAP
74.86M
P/E (TTM)
-1.5584
1D
5D
1M
3M
1Y
5Y
LCID, SDC and ABCL among pre market gainers
Corvus Pharmaceuticals (NASDAQ:CRVS) +56%. Innate Pharma (NASDAQ:IPHA) +32% Monalizumab data from COAST trial presented at ESMO Congress 2021 Surface Oncology (NASDAQ:SURF) +14%. BeiGene (NASDAQ:BGNE) +13% on positive DKN-01 + tislelizumab data in gastroes...
Seekingalpha · 3d ago
Achieve Life Sciences to Participate in Upcoming Investor Conferences
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 15, 2021/ Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotin...
ACCESSWIRE · 5d ago
Achieve Life Sciences Announces Presentation of Cytisinicline Data at the 21st Annual Society for Research on Nicotine & Tobacco (SRNT-E) Virtual Conference
SEATTLE, WA & VANCOUVER, BC / ACCESSWIRE / September 14, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine...
ACCESSWIRE · 6d ago
Achieve Life Sciences to Participate in Two Upcoming Investor Conferences
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / September 9, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotin...
ACCESSWIRE · 09/09 09:30
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
ACHV: ORCA-2 Fully Enrolled
By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Second Quarter 2021 Results Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported second quarter results in a press release and held a conference call after market close on August 12, 20...
Zacks Small Cap Research · 08/16 09:10
Achieve Life Sciences Announced Expansion of Cytisinicline Clinical Operations Team
Achieve Life Sciences, Inc. (NASDAQ: ACHV) today announced that the Company has expanded its Clinical Operations Team with the hiring of a Director of Clinical Operations, a Senior Manager of Clinical Trials, and a Senior Director of Biometrics.
Benzinga · 08/13 09:33
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACHV. Analyze the recent business situations of Achieve through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACHV stock price target is 36.71 with a high estimate of 80.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 46
Institutional Holdings: 2.57M
% Owned: 27.22%
Shares Outstanding: 9.45M
TypeInstitutionsShares
Increased
8
550.23K
New
17
769.55K
Decreased
3
48.20K
Sold Out
4
330.30K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.58%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Executive Director
Richard Stewart
President/Director
Cindy Jacobs
Chief Executive Officer/Director
John Bencich
Chief Accounting Officer
Jerry Wan
Chief Scientific Officer
Anthony Clarke
Lead Director/Independent Director
Donald Joseph
Independent Director
Bridget Martell
Independent Director
Martin Mattingly
Independent Director
Jay Moyes
No Data
About ACHV
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in development and commercialization of cytisinicline for smoking cessation and nicotine addiction. The Company’s product candidate, cytisinicline, is a naturally occurring, plant-based alkaloid from the seeds of the Laburnum anagyroides plant. Cytisinicline is structurally similar to nicotine and a mechanism of action that is both agonistic and antagonistic. It is aid in smoking cessation, or nicotine addiction, by interacting with nicotine receptors in the brain by reducing the severity of nicotine withdrawal symptoms through agonistic effects on nicotine receptors and by reducing the reward and satisfaction associated with nicotine through antagonistic properties.

Webull offers kinds of Achieve Life Sciences Inc stock information, including NASDAQ:ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.